INSILICO (03696): Fully exercise the over-allotment option
(03696) announced that the sponsoring and overall coordinator (acting on behalf of itself and representing international underwriters) has fully exercised the excess share subscription rights as described in the prospectus on January 16, 2026, involving a total of 14.2035 million shares, accounting for approximately 15% of the initial total number of shares available for subscription under the global offering (before exercising the excess share subscription rights).
INSILICO (03696) announced that the sponsor and overall coordinator (on behalf of itself and the international underwriters) has fully exercised the oversubscription rights as set out in the prospectus on January 16, 2026, involving a total of 14.2035 million shares, representing approximately 15% of the total number of shares available for subscription under the global offering (before exercising the oversubscription rights). The oversubscribed shares will be issued and distributed by the company at a price of HK$24.05 per share. The oversubscribed shares will be used to facilitate the return of the 14.2035 million borrowed shares under the stock lending agreement dated December 24, 2025 between Mr. Aleksandrs Zavoronkovs and MORGAN STANLEY & CO INTERNATIONAL PLC, used to supplement the oversubscription in the international offering.
Related Articles

Linzhou Heavy Machinery Group (002535.SZ) terminates the matter of non-publicly issuing shares in 2025.

Haisco Pharmaceutical Group (002653.SZ) has obtained two indications for the innovative drug HSK44459 cream, with IND applications accepted.

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.
Linzhou Heavy Machinery Group (002535.SZ) terminates the matter of non-publicly issuing shares in 2025.

Haisco Pharmaceutical Group (002653.SZ) has obtained two indications for the innovative drug HSK44459 cream, with IND applications accepted.

Haisco Pharmaceutical Group (002653.SZ): Innovative drug HSK31679 tablet included in breakthrough therapy program.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


